C. de Zwaan - Concepedia

Concepedia

Author

C. de Zwaan

Maastricht University

Also Known As

C De Zwaan, C ZWAAN, C de Zwaan, C. DE ZWAAN, C. de Zwaan, C.De Zwaan, Christoffel de Zwaan

33

Publications

1.9K

Citations

17

H-Index

37

Concepts

All Affiliations

Maastricht University Maastricht University Medical Centre University of Amsterdam Netherlands Heart Institute Leiden University

CD

About

C. de Zwaan is an author at Maastricht University specializing in cardiovascular disease, medicine, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.3K
2	Emergency Medicine	8	8	1.1K
3	Public Health	6	6	610
4	Health Sciences	1	1	26
5	Immunology	1	1	52

C. de Zwaan

×

19

Publications

1.9K

Citations

17

H-Index

	Year	Citations
IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION Maarten L. Simoons, Marcel v.d. Brand, C. de Zwaan, The Lancet ThrombosisVenous ThrombosisCardiovascular DiseaseAtherosclerosisMedicine	1985	453
Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Jacobus Lubsen, Jan G.P. Tijssen, Johan J. Kerkkamp, Heart	1986	270
Value of electrocardiogram in diagnosing right ventricular involvement in patients with an acute inferior wall myocardial infarction. Simon H. Braat, Pedro Brugada, C. de Zwaan, Heart Heart FailureCardiogenic ShockCardiovascular DiseaseMyocardial InfarctionLead Electrocardiogram	1983	223
Right ventricular involvement with acute inferior wall myocardial infarction identifies high risk of developing atrioventricular nodal conduction disturbances Simon H. Braat, C. de Zwaan, Pedro Brugada, American Heart Journal CardiomyopathyHeart FailureCardiogenic ShockCardiovascular DiseaseMyocardial Infarction	1984	140
Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase? Frank Vermeer, Maarten L. Simoons, Frits W. Bär, Circulation Which PatientsHeart FailurePharmacotherapyCoronary Artery DiseaseAcute Myocardial Infarction	1986	133
Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction C. de Zwaan European Heart Journal	2002	97
Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Frits W. Bär, Freek W.A. Verheugt, J. Col, Circulation	1992	90
Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: A randomized trial of 533 patients with acute myocardial infarction Arnoud van der Laarse, Frank Vermeer, W.Th. Hermens, American Heart Journal ThrombosisCardiovascular DiseaseAtherosclerosisMedicineEnzyme Release Rate	1986	60
Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. Frank Vermeer, Maarten L. Simoons, C. de Zwaan, Heart	1988	60
Treatment with a GPIIb/IIIa Antagonist Inhibits Thrombin Generation in Platelet Rich Plasma from Patients I. Keularts, C. de Zwaan, H.C. Hemker Thrombosis and Haemostasis ImmunologyPharmacotherapyInflammationThrombosisFree Thrombin	1998	52

Page 1